Skip to content

Debt-to-assets at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
0.2×+0.1×
Biogen logo
BiogenBIIB
0.2×0.0×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
0.0×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
0.0×
uniQure logo
uniQureQURE
0.1×0.0×
Precigen logo
PrecigenPGEN
0.7×+0.7×

Other financials

Income statement

See full
Revenue--100%
Operating income-$43.5M-103%
Net income-$42.4M-97.0%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total equity$211.9M+285%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation

See full
Market cap$1.97B+351%
Enterprise value$1.76B+368%
P/S263.9×+203×

Profitability

See full
Operating margin-1,774.4%+1,437pp
Net margin-1,738.4%+1,407pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

Where this comes from

Calculated from Taysha Gene Therapies, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Taysha Gene Therapies, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Taysha Gene Therapies, Inc.'s debt-to-assets?
Taysha Gene Therapies, Inc. (TSHA) reported debt-to-assets of 0.2× in Q1 2026.
How has Taysha Gene Therapies, Inc.'s debt-to-assets changed year-over-year?
Taysha Gene Therapies, Inc.'s debt-to-assets decreased by 48.8% year-over-year, from 0.4× to 0.2×.
What is the long-term trend for Taysha Gene Therapies, Inc.'s debt-to-assets?
Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s debt-to-assets has grown at a 4.1% compound annual growth rate (CAGR), from 0.2× to 0.2×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.